Lyra Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Lyra Therapeutics

07/05/2025 12:01

Lyra Therapeutics Inc LYRA.OQ LYRA.O is expected to show a fall in quarterly revenue when it reports  results  for the period ending June 30 2025

The Watertown Massachusetts-based  company is expected to report a 59.5% decrease in revenue to $242 thousand from $598 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lyra Therapeutics Inc is for a loss of 14 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 18.8% in the last three months. ​

Wall Street's median 12-month price target for Lyra Therapeutics Inc is $2.00​, above​ its last closing price of $0.10. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.15
-0.14
-0.12
Beat
12.2
Dec. 31 2025
-0.13
-0.12
-0.16
Missed
-33.3
Sep. 30 2024
-0.21
-0.23
-0.18
Beat
21.1​
Jun. 30 2024
-0.33
-0.33
-0.74
Missed
-125.6
​​Mar. 31 2024
-0.27
-0.26
-0.35
Missed
-33.6
Dec. 31 2023
-0.31
-0.22
Beat
30.2​
Sep. 30 2023
-0.31
-0.32
-0.27
Beat
15.1
Jun. 30 2023
-0.40
-0.42
-0.32
Beat
24.4

This summary was machine generated May 7 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)